Back

Nimesh Pinnamaneni
•

Helixworks Technologies • 2d

From ₹51 Cr to ₹1,272 Cr in a year—this Indian biotech’s revenue chart is insane. 💰 Molbio is going public targeting ₹22,000–24,000 Cr valuation. IPO expected in November 2025, raising ₹2,200–2,400 Cr. 🔬 Their Truenat platform, is a battery-power

Anonymous 4

Hey I am on Medial • 2d

As someone who actually used both Cepheid and Truenat systems during COVID (I work in hospital administration), there are significant differences. Cepheid is more user-friendly with fully integrated cartridges but costs 3-4x more per test. Truenat re

Nimesh Pinnamaneni
•

Helixworks Technologies • 2d

Interesting insight on their go-to-market. I thought Truenat is also a sample-to-answer solution—doesn’t require any pre-processing. Is the manual step you’re referring to in nucleic acid extraction, or something else?

0 replies

Recommendations from Medial

Niket Raj Dwivedi
•

Medial • 10m

Medial is rolling out a patch today to fix a lot of bugs and some more improvements. Now you’ll require only 50% profile completion to access DM’s. Some tech glitches will be fixed. Please note- If your company or college name doesn’t showup wh

13 replies11 likes

Nimesh Pinnamaneni
•

Helixworks Technologies • 7d

Why qPCR & Phenotypic Testing Must Be Displaced? – Part III This is the third part of a deep dive into why qPCR & phenotypic testing need to be replaced. In Part I, I covered the limitations of current diagnostics & why incremental improvements aren